Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment

Somatostatin receptor 2 (SSTR2), the most abundant receptor of somatostatin (SST), possesses immunoreactivity and is altered in many cancers. However, the association between SSTR2 and efficacy of immune checkpoint inhibitors (ICIs) has not yet been reported. Immunohistochemistry (IHC) information a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Aoyun, Yuan, Yixiao, Chu, Han, Gao, Yixing, Jin, Zheng, Jia, Qingzhu, Zhu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898825/
https://www.ncbi.nlm.nih.gov/pubmed/35264912
http://dx.doi.org/10.3389/pore.2022.1610196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898825/
https://www.ncbi.nlm.nih.gov/pubmed/35264912
http://dx.doi.org/10.3389/pore.2022.1610196

Ejemplares similares